ArticleBMC gastroenterology2026
Early warning value of serum TFF3 combined with pepsinogen ratio for monitoring the progression of gastric precancerous lesions: a retrospective study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGastric cancer (GC) has high mortality due to late diagnosis. Identifying which patients with gastric low-grade intraepithelial neoplasia (LGIN) will progress to high-grade intraepithelial neoplasia (HGIN) or early gastric cancer (EGC) remains challenging. This study aimed to develop a non-invasive method combining serum TFF3 (reflecting malignant transformation) and pepsinogen ratio (PGR, indicating gastric atrophy) to predict progression.
methodsA retrospective multicenter study included patients with confirmed LGIN, available serum, and full follow-up. Progression to HGIN/EGC within 24 months was the primary outcome. TFF3 and PGR were measured using ELISA and chemiluminescence immunoassay, respectively. Propensity score matching (1:4) balanced baseline variables. Predictive performance was assessed via ROC analysis, logistic regression, and Cox models.
resultsAfter matching, 85 patients (17 progressors) were analyzed. Progressors had higher TFF3 (11.28 vs. 7.15 ng/mL) and lower PGR (2.78 vs. 3.62; both p < 0.001). The combined model showed superior accuracy (AUC = 0.823) versus TFF3 or PGR alone, with sensitivity of 88.2%, specificity of 89.7%, and NPV of 98.3. Progressors exhibited yearly TFF3 increase (+ 1.82 ng/mL) and PGR decrease (-0.41). TFF3 correlated with Ki-67 (ρ = 0.437, p < 0.001).
conclusionThe TFF3 and PGR combination is a non-invasive tool for stratifying LGIN progression risk. Its high NPV safely excludes short-term progression, enabling extended follow-up for low-risk patients and better allocation of endoscopic resources. This approach supports personalized monitoring and may help reduce gastric cancer mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.